Biochemical Premotor Biomarkers for Parkinson's Disease

Overview

Journal Mov Disord

Date 2012 Apr 18

PMID 22508282

Citations 13

Authors

Brit Mollenhauer

Jing Zhang

Affiliations

Soon will be listed here.

Abstract

A biomarker is a biological characteristic that is objectively measured and evaluated as an indicator of normal biological or pathologic processes or of pharmacologic responses to a therapeutic intervention. We reviewed the current status of target protein biomarkers (eg, total/oligomeric α-synuclein and DJ-1) in cerebrospinal fluid, as well as on unbiased processes that can be used to discover novel biomarkers. We have also provide details about strategies toward potential populations/models and technologies, including the need for standardized sampling techniques, to pursue the identification of new biochemical markers in the premotor stage of Parkinson's disease in the future.

Citing Articles

Serum metabolomics analysis revealed metabolic disorders in Parkinson's disease.

Lan T, Chang L, Hou L, Wang Z, Li D, Ren Z Medicine (Baltimore). 2023; 102(23):e33715.

PMID: 37335671 PMC: 10256383. DOI: 10.1097/MD.0000000000033715.

Searching for Biomarkers in the Blood of Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage.

Katunina E, Blokhin V, Nodel M, Pavlova E, Kalinkin A, Kucheryanu V Int J Mol Sci. 2023; 24(3).

PMID: 36768161 PMC: 9915927. DOI: 10.3390/ijms24031842.

Synuclein-One study: skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies.

Gibbons C, Freeman R, Bellaire B, Adler C, Moore D, Levine T Biomark Med. 2022; 16(7):499-509.

PMID: 35272481 PMC: 9169016. DOI: 10.2217/bmm-2021-0646.

Modulation of the Interactions Between α-Synuclein and Lipid Membranes by Post-translational Modifications.

Bell R, Vendruscolo M Front Neurol. 2021; 12:661117.

PMID: 34335440 PMC: 8319954. DOI: 10.3389/fneur.2021.661117.

What about biomarkers for parkinson's disease?.

Madireddy N, Posa D, Naik S, Lippmann S Innov Clin Neurosci. 2021; 18(1-3):9-10.

PMID: 34150356 PMC: 8195565.

References

Scherzer C, Eklund A, Morse L, Liao Z, Locascio J, Fefer D . Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007; 104(3):955-60. PMC: 1766335. DOI: 10.1073/pnas.0610204104. View

El-Agnaf O, Salem S, Paleologou K, Curran M, Gibson M, Court J . Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006; 20(3):419-25. DOI: 10.1096/fj.03-1449com. View

Yu S, Lo E, Cochran E, Lin D, Faselis C, Klawans H . Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture. Exp Neurol. 1994; 126(1):15-24. DOI: 10.1006/exnr.1994.1038. View

Shi M, Jin J, Wang Y, Beyer R, Kitsou E, Albin R . Mortalin: a protein associated with progression of Parkinson disease?. J Neuropathol Exp Neurol. 2008; 67(2):117-24. DOI: 10.1097/nen.0b013e318163354a. View

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

Aerts M, Esselink R, Abdo W, Bloem B, Verbeek M . CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging. 2011; 33(2):430.e1-3. DOI: 10.1016/j.neurobiolaging.2010.12.001. View

Dehay B, Bezard E . New animal models of Parkinson's disease. Mov Disord. 2011; 26(7):1198-1205. DOI: 10.1002/mds.23546. View

Pan S, Rush J, Peskind E, Galasko D, Chung K, Quinn J . Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008; 7(2):720-30. DOI: 10.1021/pr700630x. View

Scherzer C, Grass J, Liao Z, Pepivani I, Zheng B, Eklund A . GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A. 2008; 105(31):10907-12. PMC: 2504800. DOI: 10.1073/pnas.0802437105. View

10.

Klucken J, Shin Y, Masliah E, Hyman B, McLean P . Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem. 2004; 279(24):25497-502. DOI: 10.1074/jbc.M400255200. View

11.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B . Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001; 58(3):373-9. DOI: 10.1001/archneur.58.3.373. View

12.

Masilamoni G, Bogenpohl J, Alagille D, Delevich K, Tamagnan G, Votaw J . Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain. 2011; 134(Pt 7):2057-73. PMC: 3122374. DOI: 10.1093/brain/awr137. View

13.

Reiber H . Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci. 1994; 122(2):189-203. DOI: 10.1016/0022-510x(94)90298-4. View

14.

Grimm J, Mueller A, Hefti F, Rosenthal A . Molecular basis for catecholaminergic neuron diversity. Proc Natl Acad Sci U S A. 2004; 101(38):13891-6. PMC: 518849. DOI: 10.1073/pnas.0405340101. View

15.

Waragai M, Wei J, Fujita M, Nakai M, Ho G, Masliah E . Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun. 2006; 345(3):967-72. DOI: 10.1016/j.bbrc.2006.05.011. View

16.

Desplats P, Lee H, Bae E, Patrick C, Rockenstein E, Crews L . Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009; 106(31):13010-5. PMC: 2722313. DOI: 10.1073/pnas.0903691106. View

17.

Ascherio A, LeWitt P, Xu K, Eberly S, Watts A, Matson W . Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009; 66(12):1460-8. PMC: 2795011. DOI: 10.1001/archneurol.2009.247. View

18.

Valappil R, Black J, Broderick M, Carrillo O, Frenette E, Sullivan S . Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord. 2010; 25(14):2296-303. DOI: 10.1002/mds.23348. View

19.

Tokuda T, Qureshi M, Ardah M, Varghese S, Shehab S, Kasai T . Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010; 75(20):1766-72. DOI: 10.1212/WNL.0b013e3181fd613b. View

20.

Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B . Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2004; 51(2):336-45. DOI: 10.1373/clinchem.2004.039347. View